Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

614
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
614
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

589
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
589
Structure and Function of Platelets01:18

Structure and Function of Platelets

5.5K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
5.5K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

654
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
654

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defective acid hydrolase secretion in RUNX1 haplodeficiency: Evidence for a global platelet secretory defect.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Intramedullary megakaryocytes internalize released platelet factor 4 and store it in alpha granules.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.

Cancer gene therapy·2014
Same author

Apoptotic effects of platelet factor VIII on megakaryopoiesis: implications for a modified human FVIII for platelet-based gene therapy.

Journal of thrombosis and haemostasis : JTH·2014
Same author

The disulfide isomerase ERp57 is required for fibrin deposition in vivo.

Journal of thrombosis and haemostasis : JTH·2014
Same journal

The Natural Mutation Arg221aTrp in Human α-Thrombin Abrogates Physiological Na<sup>+</sup> Binding and Preferentially Hinders the Protease Anticoagulant Functions.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

A historical review of the biological, semantic and clinical aspects of aspirin resistance.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Association between Thrombus Neutrophil Extracellular Traps Content and Ischemic Stroke Recurrence.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Peptide-Mediated Inhibition of Surface-Initiated Thrombogenesis.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Growth differentiation factor-15 and bleeding risk in patients with venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Physiological Anticoagulant Deficiencies: Pathogenesis, Diagnosis, and Clinical Implications.

Journal of thrombosis and haemostasis : JTH·2026
See all related articles

Related Experiment Video

Updated: Apr 7, 2026

Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.7K

Platelet-delivered therapeutics.

R Lyde1,2, D Sabatino1,3, S K Sullivan4

  • 1Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Journal of Thrombosis and Haemostasis : JTH
|July 8, 2015
PubMed
Summary
This summary is machine-generated.

Modified platelets offer a novel approach for treating platelet disorders and delivering therapeutics to vascular injury sites. This strategy shows promise for conditions like hemophilia A and thromboprophylaxis.

Keywords:
factor VIIIfibrinolysisgene therapyhemophiliaplateleturokinase

More Related Videos

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.3K
Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
05:57

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

5.3K

Related Experiment Videos

Last Updated: Apr 7, 2026

Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.7K
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.3K
Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
05:57

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

5.3K

Area of Science:

  • Biotechnology
  • Hematology
  • Vascular Biology

Background:

  • Platelets play crucial roles in hemostasis and vascular repair.
  • Intrinsic platelet defects and vascular injuries present significant clinical challenges.
  • Current therapeutic strategies have limitations in targeted delivery and efficacy.

Purpose of the Study:

  • To explore the potential of modified platelets for correcting intrinsic platelet defects.
  • To investigate the use of engineered platelets for targeted delivery of therapeutic molecules to vascular injury sites.
  • To discuss applications in thromboprophylaxis and hemophilia A treatment.

Main Methods:

  • Ectopic expression of therapeutic proteins (urokinase, Factor VIII, Factor IX) within platelet alpha-granules.
  • Platelet activation as a trigger for therapeutic molecule release.
  • Review of strategies for targeted delivery to sites of vascular injury.

Main Results:

  • Successful ectopic expression of several proteins, including urokinase and Factor VIII, in platelet alpha-granules has been achieved.
  • Demonstrated potential for targeted delivery of urokinase for thromboprophylaxis.
  • Showcased potential for Factor VIII delivery in hemophilia A patients with inhibitors.

Conclusions:

  • Modified platelets represent a promising platform for treating platelet disorders and vascular conditions.
  • Targeted delivery of therapeutics via engineered platelets offers new avenues for managing hemophilia A and preventing thrombosis.
  • Further research is needed to address remaining challenges and limitations for clinical application.